Advances in tumour diagnosis and treatment, particularly targeted drugs, have considerably improved renal cell carcinoma (RCC) survival while increasing the incidence of hypertension (HTN). As a result, identifying risk factors and enhancing therapeutic treatment for RCC and HTN patients are critical challenges. This study looked at both preclinical and clinical risk factors for HTN-RCC comorbidity. Obesity, smoking, and other lifestyle choices may be risk factors for both RCC and HTN. Second, RCC and HTN medications can interact with one another. Then, HTN treatment and RCC comorbidity reduction were addressed. Additionally discussed current study flaws and potential directions Finally, the goal of this study is to expand cardio-oncology knowledge and to help patients who are at high risk of or suffering from RCC and HTN.